FTC approves Mylan's hostile Perrigo bid; Eylea leap pulls Regeneron sales up 57%;

@FiercePharma: GSK's vaccine unit sees revenue, profit jump in Q3. More from FierceVaccines | Follow @FiercePharma

@CarlyHFierce: Good thing Bayer's in Germany, CEO says. U.S. business culture is too impatient. Story | Follow @CarlyHFierce

> The FTC has approved Mylan's ($MYL) hostile bid for Perrigo ($PRGO) under the condition that Mylan sell 7 drugs to Alvogen. Report

> Another surge in Eylea sales drove Regeneron ($REGN) to a 57% increase in Q3 revenue, and net income more than doubled. Report

> Johnson & Johnson's ($JNJ) Janssen unit submitted an application for expanded European approval of its blood cancer drug Imbruvica, as a therapy for previously untreated patients with chronic lymphocytic leukemia. Release

Medical Device News

@FierceMedDev: Roche launches rapid HIV, hep C tests in Europe. Article | Follow @FierceMedDev

@VarunSaxena2: Medtronic releases health economics study of its drug-coated balloon at Las Vegas conference. Story | Follow @VarunSaxena2

@EmilyWFierce: Does AstraZeneca own the color purple? On a pill, yes, the company contends. FiercePharmaMarketing story | Follow @EmilyWFierce

> Theranos CEO heeds call for transparency for proprietary technology. Article

> Medtronic axes 150 jobs in new Irish tax domicile. News

Biotech News

@FierceBiotech: Biogen spells out its moonshot R&D strategy amid deep cost cuts. More | Follow @FierceBiotech

@JohnCFierce: Oxford team spotlights promise of AstraZeneca drug in targeting cancers. FierceBiotechResearch article | Follow @JohnCFierce

> Flagship launches another microbiome biotech with $35M and a focus on cancer. Report

> Allergan bets $50M on a dry eye drug as it touts its commitment to R&D. Story

> Vertex looks to gene therapy, RNA deals to quash takeover talk. Article

Pharma Marketing News

> GlaxoSmithKline's HIV bright spot could get brighter with new Tivicay combo meds. Item

> Viewers skeptical of DTC ads, but they drive people to docs anyway. More

> Bristol-Myers Q3 ad spending pushes up to $193M on renewed promotions push. Story

> Pfizer launches first Prevnar TV spot to bring in the 50-plus crowd. Report

> Does AstraZeneca own the color purple? On a pill, yes, the company contends. Article

Biotech Research News

> Neat 'trick' guards peptides against early degradation. Story

> JAK inhibitors target senescent cells in aging study. Item

> Small molecule used to blunt glioblastoma growth in mice--UCSD. More

> Researchers devise heat-triggered liposome 'grenades' to destroy cancer cells. Story

> UPenn researchers show importance of calcium signaling for Ebola virus. Article

Vaccines News

> Takeda, Hilleman eye low-cost vaccine space. News

> Sanofi expects first dengue vaccine license in Q4. Item

> Pfizer teams up with the Biovac Institute to produce Prevenar 13 in South Africa. Report

> GSK's vaccine unit sees revenue, profit jump in Q3. Story

> European Commission launches €23M HIV vaccine research initiative. Article

And Finally... These days, it's common to see several drugs racing for a first-in-class approval, which means that small accelerations in R&D can yield big payoffs, a Tufts University study found. Report

Suggested Articles

The company will commit $300 million over the next five years to hire more people of color and increase clinical trial diversity.

Moderna, after tapping almost $1 billion in federal funding, agreed to deliver 100 million doses of its vaccine candidate for up to $1.5 billion.

FDA advisors will question the clinical data and manufacturing for Mesoblast's Ryoncil, a cell therapy for pediatric acute graft vs. host disease.